ArQule
AcquiredBurlington, United States · Founded 1993
- Headquarters
- Burlington, Massachusetts
- Employees
- 1–10
- Founded
- 1993
- Business Model
- B2B
- Website
- arqule.com
About
Incorporated in 1993 and headquartered in Burlington, Massachusetts, ArQule was one of the first biotech companies to focus on the chemistry aspect of drug discovery for cancer. The company developed targeted therapeutics for cancers and rare diseases using a kinase inhibitor platform, with its lead compound ARQ 531 showing durable responses in patients with B-cell malignancies. Merck acquired ArQule in January 2020 for approximately $2.7 billion, adding ARQ 531 (later nemtabrutinib) to its oncology pipeline.
Summary
ArQule is an oncology company based in Burlington, United States, founded in 1993.
Similar Companies
Novel bicyclic peptides and drug conjugates for cancer
BridgeBio makes targeted treatments for genetic diseases.
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...